Posterior Segment Company Showcase - Notal vision at OIS@AAO 2016. Presenter: Quinton Oswald, CEO Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

1. Quinton Oswald
Chief Executive Officer
O I S @ AAO
O c t o b e r 1 3 2 0 1 6

2. [ 2 ]
A NEW PARADIGM FOR THE
Detection
of Ocular Diseases
FI RST APPLI C ATI ON
Age-Related Macular Degeneration (AMD)
The #1 Cause of Vision Loss in People 60+*
… in diseases where early detection
can dramatically affect outome
* In developed countries
P H Y S I C I A N - D R I V E N
Diagnosis and Treatment
PAT I E N T- A C T I VAT E D
Detection
T E C H N O L O G Y - E N A B L E D

3. [ 3 ]
AMD Innovation Focused on
Physician-Driven Diagnosis and Treatment
1MarketsandMarkets Report 2 GlobalData estimate of 2023 AMD Global Treatment Market
ACCURATE
DIAGNOSIS
EFFECTIVE
TREATMENT
Optical Coherence
Tomography
(OCT)
Anti-VEGFs
and
Future Novel
Therapies
Driving
Significant Markets HOWEVER:
$1B1
~$10B2
Detection Is
Not Timely
Treatment
Demonstrates Efficacy
but Functional Vision
May Never Be
Restored

4. [ 4 ]
Broad Macro Trends Support Focus on
Patient Empowerment
2
Technology-Enabled
Remote
Detection and Diagnosis
1
Earlier Disease
Detection Drives
Better Outcomes
3
Reimbursement
Becomes
Outcomes-Driven
$ $

5. [ 5 ]
Visual
Acuity
Severe
Vision
Loss
Dry AMD Wet AMD
Downward
Cascade in Vision
Loss May Go
Unnoticed by
Patients
The Challenge: Timely Detection of Wet AMD
Slow
Progression
Rapid
Progression
Therapeutics (e.g. Anti
VEGFs)
Treat Wet Form Only
Within Weeks:
Narrow Window to Detect
Transition from Wet  Dry
Finding Patients at the Turning
Point of Disease …
… So Early Treatment Can
Preserve Functional Vision
… 36 Million Globally with AMD
THE DETECTION ‘LOTTERY’
THE CHALLENGE:

6. [ 6 ]
Today: Vast Majority of Wet AMD Patients
Are Diagnosed Too Late
Driving Threshold
i.e., ‘Functional Vision’
Normal
Legal
Blindness
20/200
20/40
20/20
TODAY’S REALITY
Lost with Late Dx Gained with Tx
-18 Letters
+8 Letters
~70%
*
Below
20/40
20/40+
No Longer Have
Functional Vision at
Diagnosis
BASELINE
May Not Regain Functional
Vision with Treatment
… and
* Analysis of Multiple AMD Studies

7. [ 7 ]
Current Disease Detection Options
Are Too Infrequent or Insensitive
Low
High
CLINICAL
ROBUSTNESS
HighLow CONVENIENCE / FREQUENCY
Household
Items
Amsler Grid
Smartphone Apps
At Home
Patient-Activated
Detection
The Holy Grail
In-Office OCT
Physician-Driven
Diagnosis

8. [ 8 ]
CLINICAL
ROBUSTNESS
• 94% Maintained
Functional Vision
(20/40+) in NIH Study
• Objective measure
• Sensitive
Our Pioneering Innovation: Patient-Activated,
Clinically Robust Early Disease Detection
CONVENIENCE
• 3 minute test per eye
• Unique design tailored to
older patient population
– Device and Technology
ecosystem
• “Plug and play”
• Results sent directly
to physician
PROVEN
Preferential Hyperacuity Perimetry
(PHP)
Detects Onset of Neovascular Leakage within
DAYS vs. Week / Months Before Patients Would
Notice Change
3,000+
Patients
2 Million
Tests
4-5x/Week
(for avg. 3.3 yrs)

FDA
Cleared

CE
Marked

Medicare
Coverage

9. [ 9 ]
Alert – in event of statistically
significant change
5Reminder
calls
3
CLOUD HOSTING
Notal Vision
Data Monitoring
Center
A Complete, Personalized Monitoring System
Early Detection in Action
OUR ENGINE ROOM IN THE CLOUD
• High touch
• Technology-enabled
• Scalable
• Compliant and secure
• Fully integrated billing/reimbursement
1 Patient takes test daily
PHYSICIAN
Physician office calls patient
for office visit and treatment
6
Data automatically
sent via embedded
cellular modem
2 Ongoing monitoring
• Monthly reports pushed
• Online access
4
PATIENT

10. [ 10 ]
COMPLEMENTARY
Finally Completing the Missing Link
for AMD Treatment and Diagnosis
PHYSICIAN-DRIVEN
Formal Diagnosis
and Treatment with
Effective Current and
Future Therapies
2006
PATIENT-ACTIVATED
Convenient, Objective,
Accurate Early Detection
2016
THE NEW
REALITY
Taking AMD Treatment to
the Next Level
...
Shift from
Regaining Vision ...
...to Not Losing It in
the First Place
Enabling
Timely Treatment

11. THANK YOU
QUINTON OSWALD, CEO
QOswald@notalvision.com
(650) 255-4557

12. [ 12 ]